Nano-X Imaging Ltd. (NNOX), an Israel-based developer of digital X-ray imaging systems and teleradiology services, has seen its share price collapse over the past year, falling roughly 92% to about $0.24. Against that backdrop, the handful of Wall Street price targets still on the books — which cluster around $3 to $5 — look disconnected from the market's current assessment. Whether NNOX can reclaim even the lower end of that range depends almost entirely on whether the company can stabilize its balance sheet and preserve its Nasdaq listing.
The central target of $4.35 is my own calculation, not an official published consensus. It is the arithmetic mean of three individually verifiable price targets: $3.00 from Alliance Global Partners (which downgraded the stock to Neutral in July 2026), $5.00 from Cantor Fitzgerald (Overweight, reiterated in August 2026), and $5.00 from D. Boral Capital (Buy, issued in March 2026). The mean of $4.33 rounds to $4.35, with an approximate range of $3.00 to $5.00.
The dispersion is telling. The most recent and cautious call — Alliance Global's $3.00 with a Neutral rating — sits well below the bullish $5.00 targets, and even the lowest target is more than ten times the current price. Aggregators such as Yahoo Finance and StockAnalysis report a broadly similar average near $4.13 from three analysts. Bullish analysts point to the company's low-cost imaging technology and early commercialization; cautious analysts emphasize heavy cash burn, negative margins, and funding risk. Notably, these targets were largely set before the stock's decline below $1, and may not reflect the company's current financial stress.
As of early November 2026, NNOX trades near $0.24, giving the company a market capitalization of roughly $19 million. Reaching $4.35 would require an advance of about 1,700% — by any measure a very large move, effectively a complete repricing of the company.
The path to such a level would require a fundamental reversal: demonstrated revenue growth, a credible path to positive gross margin and profitability, and resolution of the liquidity concerns. For the trailing twelve months, NNOX generated about $15.6 million in revenue while posting a net loss of roughly $117 million. The company has flagged substantial doubt about its ability to continue as a going concern, and has scheduled a shareholder vote on November 18, 2026 to approve both an increase in authorized shares and a reverse stock split in a 1-for-20 to 1-for-50 range.
Any recovery toward the analyst price targets would depend on a combination of factors. The company's core thesis — affordable, digital X-ray systems that could expand imaging access — remains intact, and its teleradiology business has posted revenue growth. New partnerships, regulatory clearances such as European approval, and progress on reimbursement could all improve the outlook. A successful reverse split, if paired with new financing and operating discipline, could address the Nasdaq minimum-bid requirement and buy time for the commercial story to develop.
The obstacles are substantial. NNOX has received a Nasdaq notice for trading below the $1.00 minimum bid price, with a grace period reportedly extending into early 2027. The company withdrew guidance and disclosed going-concern uncertainty, citing that its cash may not support operations for a full year. Deep losses, negative gross margins, and an active at-the-market (ATM) equity program that could dilute shareholders all weigh on the stock. A reverse split alone does not create value, and if followed by further share issuance, it could continue to pressure the share count and the price.
Technically, NNOX is in a deeply downtrodden state. The stock trades below its 50-day moving average near $0.57 and its 200-day moving average near $1.53, with a relative strength index (RSI) in oversold territory. Near-term support sits around the recent lows of roughly $0.21 to $0.24. Resistance appears first at the psychological $1.00 level — the Nasdaq listing threshold — and then at the moving averages. For the stock to mount any sustained move, it would first need to reclaim and hold above $1.00.
Analyst price targets typically reflect a roughly 12-month horizon, though the specific horizon for each firm is not always disclosed and varies by analyst. Given the company's distress, investors should focus on nearer-term catalysts: the November 18, 2026 shareholder vote on the reverse split and authorized-share increase, the next earnings report expected around November 19, 2026, and any updates on cash position, financing, and going-concern language. Reimbursement and regulatory developments, along with any Nasdaq compliance updates, are also critical.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like NNOX, such tools can help traders spot shifts in momentum and manage positions more efficiently. Traders can use these signals to discover opportunities, monitor existing holdings, and identify changing trends without manually reviewing every chart.
Can NNOX reach $4.35? The question is best framed as whether the company can first survive. The $4.35 central target is a calculated average of three analyst targets ranging from $3.00 to $5.00, and it represents a roughly 1,700% move from the current price. The bullish case rests on commercialization progress and a recapitalization that restores confidence; the bearish case centers on going-concern risk, dilution, and a possible reverse split. With analysts themselves far apart and the stock trading below the Nasdaq minimum-bid threshold, the outcome hinges less on near-term price targets and more on whether NNOX can stabilize its finances and demonstrate a viable path to sustainable revenue. No outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NNOX has been loosely correlated with RDNT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NNOX jumps, then RDNT could also see price increases.
| Ticker / NAME | Correlation To NNOX | 1D Price Change % | ||
|---|---|---|---|---|
| NNOX | 100% | +59.80% | ||
| RDNT - NNOX | 46% Loosely correlated | -0.56% | ||
| TWST - NNOX | 44% Loosely correlated | -2.37% | ||
| SMTI - NNOX | 39% Loosely correlated | -1.37% | ||
| AZTA - NNOX | 38% Loosely correlated | -1.15% | ||
| NEO - NNOX | 37% Loosely correlated | -3.64% | ||
More | ||||
| Ticker / NAME | Correlation To NNOX | 1D Price Change % |
|---|---|---|
| NNOX | 100% | +59.80% |
| Health Services category (239 stocks) | 5% Poorly correlated | +0.37% |
| Medical/Nursing Services category (138 stocks) | 4% Poorly correlated | +0.85% |